Due to the possible antianginal effect of SGLT2 inhibitors, we conducted a double‐blind, placebo‐controlled, randomized trial to evaluate the potential impact of empagliflozin on angina burden and exercise capacity in patients with both RA and T2DM, regardless of its glucose‐lowering effects. This evidence concerns the gene SLC5A2 and angina pectoris.